FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      
           
This page is updated frequently with new Immunotherapy-related patent applications. Subscribe to the Immunotherapy RSS feed to automatically get the update: related Immunotherapy RSS feeds. RSS updates for this page: Immunotherapy RSS RSS


Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies

Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies

Date/App# patent app List of recent Immunotherapy-related patents
04/23/15
20150110820
 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy patent thumbnailnew patent Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of cpavkrdvdlflt (seq id no: 1) as well as its combinations with other peptides for immunosuppressive purposes.. .
Circassia Limited
04/23/15
20150110797
 Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies patent thumbnailnew patent Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
Isolated peptides from the protein emmprin (cd147/basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders..
04/23/15
20150110761
 Expansion of alloantigen-reactive regulatory t cells patent thumbnailnew patent Expansion of alloantigen-reactive regulatory t cells
The present disclosure relates generally to the manufacture of regulatory t cells (tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive tregs ex vivo.
The Regents Of The University Of California
04/16/15
20150105325
 Recombinant alpha-fetoprotein and compositions thereof patent thumbnailRecombinant alpha-fetoprotein and compositions thereof
Disclosed are pharmaceutical and synergistic compositions comprising human recombination alpha-fetoprotein expressed in eukaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.. .
04/16/15
20150104481
 Water extract of antrodia camphorata for immunostimulatory effect and preparation method thereof patent thumbnailWater extract of antrodia camphorata for immunostimulatory effect and preparation method thereof
A preparation method for a water extract of the fruiting body of antrodia camphorata (acw) is provided. The method includes steps of: (a) providing the fruiting body; and (b) boiling the fruiting body in water to obtain the water extract.
Kaohsiung Medical University
04/09/15
20150098958
 Influenza nucleoprotein vaccines patent thumbnailInfluenza nucleoprotein vaccines
The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from influenza strain a, b or c, and a variant of a c4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease..
Imaxio
04/02/15
20150094336
 Methods for treating gliomas with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione patent thumbnailMethods for treating gliomas with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation
04/02/15
20150094335
 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent patent thumbnailMethods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation
03/26/15
20150086612
 Rna formulation for immunotherapy patent thumbnailRna formulation for immunotherapy
The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering rna to antigen presenting cells such as dendrite cells (dcs) in the spleen after systemic administration.
Biontech Ag
03/19/15
20150079027
 Antitumor protocol patent thumbnailAntitumor protocol
Improved protocols that enhance the effect of immunotherapy against tumors are described. The protocol involves enhancing the immune response to an antitumor vaccine by maximizing the ability of t cells induced by the vaccine to extravasate into the tumor and also to modulate the effect of tregs so that the effectiveness of the vaccine is not undermined.
Dendritherapeutics, Inc.
03/12/15
20150071967

Tolerisation-inducing composition


The present invention relates to a composition comprising a tolerogenic peptide and a gsk-3 inhibitor and uses thereof. The invention also relates to the use of a gsk-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines.
University Of Bristol
03/12/15
20150071873

Cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria


A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a mycobacterium bovis bacillus calmette-guerin (bcg), an antigenically related non-pathogenic mycobacteria, or one or more immunogenic component(s) thereof, as therapeutic active ingredient(s) for use in the treatment of cancer by parenteral or oral administration of the first composition to a cancer patient before local administration of the second composition at tumor site. A method in vitro for monitoring cancer treatment by immunotherapy with bcg, antigenically related non-pathogenic mycobacteria, or immunogenic component(s) thereof, comprising assaying bcg-specific immune response in a patient..
Universitatsspital Basel
03/12/15
20150071853

Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof


The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal.
Immune Pharmaceuticals Ltd.
03/05/15
20150065584

Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis


The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent.
Amderma Pharmaceuticals, Llc
03/05/15
20150064240

Muc1 based glycolipopeptide vaccine with adjuvant


Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.. .
Oncothyreon Inc.
03/05/15
20150064239

Methods for identifying modulators of il-24 mediated apoptosis and immunotherapy


A method for identifying modulators of interleukin 24 (il-24) mediated apoptosis is disclosed. For il-24 apoptosis to be effective, the cells should express sigma 1 receptor (s1r).
Research Foundation Of The City University Of New York
03/05/15
20150064219

Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells


Provided are methods for inducing an anti-tumor immune response by immunizing a mammal with a composition comprising a tumor cell which expresses a nlr ligand and/or tlr ligand-taa fusion protein or with an activated dc which has internalized a tumor cell which expresses an nlr- and/or tlr ligand-taa fusion protein.. .
Icahn School Of Medicine At Mount Sinai
03/05/15
20150064210

Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome


Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (casai) using predetermined biomarkers.. .
Dendreon Corporation
03/05/15
20150064204

Gitr antigen binding proteins


Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.
03/05/15
20150064136

Predictors of patient response to interferon-a therapy


The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (ifn) therapy is mediated in part by inhibition of activation of mdsc and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ros) production by mdsc (as a measure of their activation) after ifn therapy is predictive of overall response to immunotherapy in cancer patients..
The University Of Pittsburgh - Of The Commonwealth System Of Higher Education
02/26/15
20150056252

Composition and diagnosis and immunotherapy of lung cancer


The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic t lymphocyte specific immune response to at least one of sp17, akap-4, or pttg1 expressed by one or more lung cancer cells.. .
Texas Tech University System
02/26/15
20150056226

Immunotherapeutic agent


The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an il-2 gene or a water-soluble tgf-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy..
Catholic University Industry Academic Cooperation Foundation
02/19/15
20150050301

Contiguous overlapping peptides for treatment of house dust mites allergy


Contiguous overlapping peptides (cops) for the treatment of allergic patients by specific immunotherapy (sit) are provided from the sequence of the major allergens of house dust mites der p 1 and der p 2. Such peptides while providing all potential t cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind ige.
Anergis S.a.
02/19/15
20150050299

Methods for enhancing immune response


This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (pbt) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction.
Lankenau Institute For Medical Research
02/12/15
20150044240

P53 vaccines for the treatment of cancers


The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells.
University Of South Florida
02/12/15
20150044224

Materials and methods for differential treatment of cancer


The present invention concerns differential therapeutic treatment of cancer patients based on prognostic antigen/antibody profiles used for predicting (prognosticating) a clinical response (efficacy) and/or adverse event to an immunotherapy for treatment of a malignancy in a subject, and for treating or delaying the onset or relapse of a malignancy in a subject.. .
Serametrix Corporation
02/12/15
20150044165

Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target


The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research
01/29/15
20150031625

Targeted vectors for cancer immunotherapy


This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject.
The University Of Southern California
01/29/15
20150030534

Antibody cocktails for breast cancer radioimmunotherapy


The present invention provides compositions comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-epidermal growth factor receptor (anti-egfr), radionuclide-labeled anti-cd-44, and radionuclide-labeled anti-cd-73. Or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer..
Rutgers, The State University Of New Jersey
01/22/15
20150024006

Allogeneic cellular immunotherapy for opportunistic infection


A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells.
Immunovative Therapies, Ltd.
01/22/15
20150023993

Combination therapy using active immunotherapy


The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (mhc) class-i or class-ii. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof..
Immatics Biotechnologies Gmbh
01/22/15
20150023938

Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens


Methods for preparing ex vivo t cell cultures using il-21 compositions for use in adoptive immunotherapy are described. Addition of il-21 to cultures of non-terminally differentiated t cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of il-21 compositions and antigen presenting cells (apcs), the resulting t cell population has an enhanced antigen-specificity, and can be reintroduced into the patient.
Fred Hutchinson Cancer Research Center
01/22/15
20150023910

Granulysin in immunotherapy


Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kd granulysin thereby producing a monocyte-derived dendritic cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
01/15/15
20150017137

Drug resistant immunotherapy for treatment of a cancer


The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
Emory University
01/15/15
20150017136

Methods for engineering allogeneic and highly active t cell for immunotherapy


The present invention relates to methods for developing engineered t-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying t-cells by inactivating both genes encoding t-cell receptor and an immune checkpoint gene to unleash the potential of the immune response.
Cellectis
01/08/15
20150010613

Compositions and methods for cancer immunotherapy


The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (cdn)—that activates dcs via a recently discovered cytoplasmic receptor known as sting (stimulator of interferon genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of gm-csf. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, dc recruitment and proliferation, coupled with a potent dc activation stimulus..
Aduro Biotech
01/08/15
20150010587

Kidney-specific tumor vaccine directed against kidney tumor antigen g-250


This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California
12/25/14
20140377761

Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy


The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory t cell response or towards an effector t cell response, and methods of determining response to immunotherapy.. .
Stallergenes S.a.
12/25/14
20140377299

Immunotherapy targeting intracellular pathogens


The present invention relates to the use of immunogenic peptides comprising a t-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as c-(x)2-[cst] or [cst]-(x)2-c in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.. .
Life Sciences Research Partners Vzw
12/25/14
20140377293

Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation
12/25/14
20140377250

Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency


Compositions including at least one pnp inhibitor or at least one pnp inhibitor in combination with one or more agents identified as endogenous adjuvants useful for enhancing the potency of vaccine and cancer immunotherapies being administered for the prevention or treatment of infectious diseases or cancer. The compositions may be formulated as pharmaceutical dosage forms and components may be assembled as kits.
Nitor Therapeutics
12/25/14
20140377218

Hcv immunotherapy


The invention relates to the use of interleukin-7 (il-7), for treating hepatitis c in a patient infected with hepatitis c virus, wherein said patient has been treated or is being treated with an antiviral agent or a combination of antiviral agents that reduces viral load.. .
Cytheris
12/18/14
20140370099

Artificial antigen presenting cells having a defined and dynamic shape


Compositions and methods comprising asymmetrical artificial antigen presenting cells (aapcs) are disclosed. The non-spherical aapcs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy..
The Johns Hopkins University
12/18/14
20140370086

Sublingual immunotherapy with reduced oral itchiness


Sublingual immunotherapy (slit) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with slit, which can improve patient compliance.
12/18/14
20140370039

Il-12 immunotherapy for cancer


Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network
12/18/14
20140369940

Anti-alpha synuclein binding molecules


Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific n-terminal and c-terminal epitopes on human α-synuclein.
Biogen Idec International Neuroscience Gmbh
12/11/14
20140363470

Pharmaceutical formulations and the use thereof for the treatment of peanut allergy


The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy.
12/11/14
20140363446

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics


This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
12/04/14
20140356930

Immune system enhancing immunotherapy for the treatment of cancer


This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer..
12/04/14
20140356398

Adoptive transfer of cd8+ t cell clones derived from central memory cells


The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic t lymphocytes (ctl) preparation in a treatment-effective amount. The method comprises administering as the ctl preparation a preparation consisting essentially of an in vitro expanded primate ctl population, the ctl population enriched prior to expansion for central memory t lymphocytes, and depleted prior to expansion of effector memory t lymphocytes.
12/04/14
20140356372

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor


The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
11/27/14
20140349402

Car+ t cells genetically modified to eliminate expression of t-cell receptor and/or hla


The present invention concerns methods and compositions for immunotherapy employing a modified t cell comprising disrupted t cell receptor and/or hla and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection.
11/27/14
20140348902

Tcl1 peptides for immunotherapy


Provided are tcl1 peptides that bind to mhc i (hla-a2) on tumor cells or other antigen-presenting cells and are recognized by t-cell receptors on t cells. The tcl1 peptides may be therapeutically used to treat a cancer, such as a b cell malignancy, leukemia, or lymphoma.
11/27/14
20140348846

Anti-hla class-ib antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (ivig) useful as therapeutic ivig mimetics and methods of their use


Provided herein are compositions comprising anti-hla-ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as ivig mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-hla-ib antibodies strongly mimic ivig in immunoreactivity to hla class ia (hla-a, hla-b and hla-cw) and ib antigens (hla-e, hla-f and hla-g).
11/27/14
20140348843

Apoe immunotherapy


The present invention provides antibodies that preferentially bind to an apoe(1-272) fragment relative to apoe(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases..
11/27/14
20140348783

Vaccine immunotherapy for immune suppressed patients


A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348782

Vaccine immunotherapy for immune suppressed patients


A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348743

Monoclonal antibodies to programmed death 1 (pd-1)


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
11/20/14
20140341982

Vaccination with immuno-isolated cells producing an immunomodulator


The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example gm-csf (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals.
11/20/14
20140341978

Cancer immunotherapy


We formulated multiple tlr agonists into gvax (lethally irradiated tumor cell vaccines engineered to secrete gm-csf). Specifically, gla and r848, tlr4 and tlr7/8 agonists found to be safe in patients, were formulated with gvax (tegvax—for tlr agonists enhanced gvax), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable b16.
11/20/14
20140341931

Soluble cd27 (scd27) and the use thereof


Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of scd27 in a serum sample obtained from a subject and comparing that amount of scd27 with a control value indicative of the basal level of scd27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of scd27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor.


Popular terms: [SEARCH]

Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.5878

3532

2 - 1 - 71